论文部分内容阅读
目的探讨强化阿托伐他汀治疗对不稳定性心绞痛(UA)患者经皮冠脉介入治疗(PCI)术后可溶性OX40L(sOX40L)及冠脉事件的影响。方法选取因UA入院,并行PCI且随访至入院后180d患者286例,收集患者一般资料及测定入院及随访180d后血浆sOX40L水平,PCI前分别给予10mgpoqn、40mgpoqn阿托伐他汀或安慰剂治疗,记录患者冠脉事件。结果应用强化阿托伐他汀治疗后患者sOX40L水平较常规剂量组或对照组sOX40L降低明显,冠脉事件发生率低,冠脉事件率与sOX40L降低水平呈正相关。结论强化阿托伐他汀治疗可显著降低sOX40L水平,进而减少冠脉事件发生。
Objective To investigate the effects of enhanced atorvastatin on soluble OX40L (sOX40L) and coronary events after percutaneous coronary intervention (PCI) in patients with unstable angina (UA). Methods 286 patients 180 days after hospital admission for UA and PCI were followed up to 180 days after admission. The general data of patients and the plasma levels of sOX40L after admission and 180 days after PCI were collected. Before PCI, patients were given 10 mg POQ, 40 mg POQn atorvastatin or placebo respectively. Patients with coronary events. Results The level of sOX40L in atorvastatin group was significantly lower than that in conventional or control group. The incidence of coronary events was lower and the rate of coronary events was positively correlated with the level of sOX40L. Conclusion Atorvastatin treatment can significantly reduce sOX40L levels, thereby reducing the incidence of coronary events.